Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences has demonstrated strong growth in its key product segments, with TAVR revenues increasing 10.6% year-over-year and TMTT sales surging by 48.3%, driven by adoption of innovative technologies like Pascal and Evoque. The company projects consistent growth moving forward, with expectations of TAVR growing 6-8% and TMTT delivering $740-780 million in revenue for fiscal year 2026, indicating robust demand across its offerings. After strong results in the first half of 2025, Edwards management has enhanced confidence in achieving their previously stated sales growth targets of 8-10% year-over-year, with total expected revenues around $6.4 billion to $6.8 billion.

Bears say

Edwards Lifesciences has demonstrated a negative outlook as evidenced by its miss in adjusted operating margin, which fell to 23.7% compared to the consensus expectation of 25.9%, primarily driven by elevated SG&A expenses. Despite TAVR sales exceeding consensus by $29 million, the overall revenue performance was mixed, with Surgical Structural Heart sales underperforming expectations by approximately $4.5 million. Additionally, potential risks including slow market growth for TAVR, emerging competition, and challenges in gaining traction with new product offerings contribute to concerns regarding the company's ability to sustain revenue growth moving forward.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.